APC and P53 mutations synergise to create a therapeutic vulnerability to NOTUM inhibition in advanced colorectal cancer.

Yuhua TianXin WangZvi CramerJoshua RhoadesKatrina N EstepXianghui MaStephanie Adams-TzivelekidisBryson W KatonaF Brad JohnsonZhengquan YuM Andres BlancoChristopher J LengnerNing Li

Published in: Gut (2023)

Our findings that a single agent targeting the extracellular enzyme NOTUM is effective in treating highly aggressive, metastatic adenocarcinomas in preclinical mouse models and human organoids make NOTUM and its glypican targets therapeutic vulnerabilities in advanced CRC.

Keyphrases

endothelial cells
induced pluripotent stem cells
mouse model
squamous cell carcinoma
small cell lung cancer
climate change
cancer therapy
cell therapy
pluripotent stem cells
stem cells
mesenchymal stem cells
squamous cell